Table 1.
Cohort description.
| Characteristics | Study Population (n = 112) |
|---|---|
| Age, years, median (IQR) | 66 (65–70) |
| Male gender, n (%) | 87 (77.6) |
| White race, n (%) | 109 (97.3) |
| Length of HIV infection, years, median (IQR) | 25 (20–29) |
| CD4+ T cell count nadir, cells/mm3 | 233 (122–345) |
| Past AIDS episodes, n (%) | 27 (24.1) |
| HCV coinfection, n (%) | 21 (18.7) |
| HIV acquisition route, n (%) | |
| MSM | 61 (54.5) |
| Heterosexual | 34 (30.3) |
| IVDU | 15 (13.4) |
| Blood products | 2 (1.8) |
| Previous antiretroviral, n (%) | |
| Naïve | 6 (5.4) |
| Mono/dual regimen | 25 (22.3) |
| 2NRTI+PI | 4 (3.6) |
| 2NRTI+NNRTI | 11 (9.8) |
| 2NRTI+INSTI | 58 (51.8) |
| Reason to switch, n (%) | |
| ABC discontinuation | 41 (38.7) |
| PI discontinuation | 22 (28.2) |
| Simplification | 35 (33.1) |
| Comorbidities, n (%) | |
| Malignancy | 27 (24.1) |
| Chronic renal disease | 27 (24.1) |
| Dyslipidemia | 54 (48.2) |
| Ischemic heart disease | 19 (17.0) |
| Hypertension | 57 (50.9) |
| Obesity | 25 (22.3) |
| Cirrhosis | 3 (2.7) |
| Diabetes | 21 (18.8) |
| Osteoporosis | 30 (26.8) |
| COPD | 12 (10.7) |
| Mood disorders | 26 (23.2) |
| Neurological disorders | 24 (21.4) |
| N of comorbidities per participant, median (IQR) | 4 (2–6) |
| Multimorbidity, n (%) | 95 (84.8) |
| N of comedications per participant, median (IQR) | 4 (2–5) |
| Polypharmacy, n (%) | 39 (34.8%) |
Legend of Table 1: IQR = interquartile range, MSM = men who have sex with men, IVDU = intravenous drug use, NRTI = nucleos(t)ide reverse transcriptase inhibitors, PI = protease inhibitors, NNRTI = non nucleos(t)ide reverse transcriptase inhibitors, INSTI = integrase inhibitors, ABC = abacavir, COPD = chronic obstructive pulmonary disease, N = number.